Chemical Technology

Specifications Guide European Petrochemicals

September 12, 2022

Specifications Guide
Assessment Window: Assessments are based on the latest
information from the market up to the close of the assessment

Spotlight

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are re

OTHER WHITEPAPERS
news image

Optimizing Carbon Capture, Utilization and Storage to Meet Ambitious Sustainability Goals

whitePaper | October 5, 2022

The race to a zero carbon future is on. Global oil and gas, petrochemical and chemical companies alike have announced ambitious and broad carbon mitigation.

Read More
news image

Monitoring chemical recycling

whitePaper | April 13, 2022

To reach environmental goals regarding climate change and the circular economy, the recycling rate of plastics has to increase considerably over the coming years.

Read More
news image

Chemical Logistics Digital connections and positive reactions

whitePaper | April 8, 2020

Digitalization opens the door to a new age for the chemical industry. It paves the way for companies in the industry from material suppliers to solution and service providers. It is the driving force behind development that creates a new level of efficiency and transparency for the industry’s sensitive supply chains.

Read More
news image

Workflow Management Software for Chemical Manufacturing

whitePaper | March 6, 2023

Companies are adapting to the transformation of the chemical manufacturing industry by the digital world. This transformation coincides with challenges either to a specific organization, or the existing technology and resources.

Read More
news image

AMMONIUM NITRATE EXPLOSIONS

whitePaper | June 20, 2022

The catastrophic explosion in Beirut was one of the worst accidents caused by ammonium nitrate (AN) in history. Since the explosion, there has been a dramatic increase in interest concerning the safety aspects of AN.

Read More
news image

Shipping’s “Dirty Fuel” Stages a Comeback as Emissions Targets Loom

whitePaper | August 19, 2021

Market participants expected HSFO to play a marginal role post-IMO 2020 but this has given way to a very different reality. Platts Analytics estimates that post-IMO 2020 demand for HSFO is expected to total 26% of global marine fuel demand by 2040 despite tougher regulations by then. Download our special feature report, "Shipping's 'Dirty Fuel' Stages a Comeback as Emissions Targets Loom" and discover: 1. Drivers behind the continued demand of high sulfur fuel oil 2. Does HSFO have an expiration date in sight? 3. Global bunker fuels demand outlook 2021-2040

Read More

Spotlight

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are re

Events